Innovative AAV Manufacturing
The FUEL™ Platform
As gene therapy developers push the boundaries of innovation, manufacturing must do more than keep pace, it must evolve. At Forge, we are rethinking how manufacturing is designed and delivered, investing in manufacturing R&D to challenge the current limits on scale, efficiency, and yield.
Our FUEL™ platform is the result of that commitment. Combining proprietary technologies, proven processes, and product-specific optimizations, FUEL™ is designed to deliver more doses from every run and expand what is possible in gene therapy.
fuel progress
Get More from Every Run with the FUEL™ Platform
By leveraging a manufacturing platform that combines increased productivity with product-specific optimizations, you gain more from every run while maintaining exceptional quality.
advanced technology
pEMBR™ 2.0 Ad Helper
As one of the smallest Ad helpers commercially available at 8.9 kb, pEMBR™ 2.0 increases manufacturing efficiency, offers an improved safety profile by reducing unnecessary adenoviral components for AAV production, and is Forge-specific intellectual property.
advanced technology
Modified Rep/Caps
Designed for safety and higher AAV yields, Forge’s patent pending modified rep/cap incorporates the client-specific capsid sequence into its proprietary backbone plasmid.
advanced technology
Ignition Cells™
Our suspension HEK293 Ignition Cells™ are optimized for robust transient transfection and can achieve over 90% full capsids post-enrichment, often with undetectable particles. Ignition Cells™ are supported by fully qualified Master Cell Bank and Working Cell Bank.
Novel Capsid? Yeah, Our Platform Can Work With That
The FUEL™ platform is designed to support all serotypes, including novel capsids.
Higher Yield, Better Recovery, Same Unmatched Quality
Explore how our FUEL™ platform boosts productivity, scales seamlessly, improves recovery, and maintains consistent quality.
productivity
The FUEL™ platform and product-specific optimizations can increase productivity 6-22x.
scalability
The FUEL™ platform offers seamless transitions across development stages, providing developers with reliable and scalable production.
quality & recovery
The FUEL™ platform provides increased recovery and consistent quality attributes.
Product-Specific Optimizations
The FUEL™ platform offers a strong foundation for further enhancements, combining platform technologies with product-specific optimizations to help you achieve high yield, consistent quality, and reliable performance. Here are some of the optimizations we’ve used to help developers achieve their goals.
Yield Optimization
Downstream Scalability
Downstream Recovery
Insights
Access Deeper Insights on the FUEL™ Platform
Ready to Fuel Your Program?
Let’s talk about how we can help accelerate your therapy to patients.
Frequently Asked Questions
How does the FUEL™ platform contribute to more efficient and scalable manufacturing?
The FUEL™ platform has the potential to deliver higher AAV yields per liter, allowing developers to achieve their required clinical vector quantities with a substantial decrease in bioreactor volume.
What is Forge’s FUEL™ platform, and how does it support AAV manufacturing?
The FUEL™ platform is Forge’s advanced AAV manufacturing solution designed to increase yields, improve scalability, and enhance efficiency. It combines Forge’s proprietary technologies, proven manufacturing processes, and product-specific optimizations to help gene therapy developers bring more therapies to more patients
Is the FUEL™ platform suitable for pre-clinical to commercial manufacturing?
Yes. The FUEL™ platform uses commercially viable technologies and processes designed to seamlessly scale from early-stage AAV manufacturing through to commercial production.
Can the FUEL™ platform be customized for my specific AAV serotype or program needs?
Absolutely. The FUEL™ AAV platform is designed to support all serotypes, including novel capsids.
What production scales can the FUEL™ platform accomodate?
The FUEL™ AAV platform supports manufacturing from small-scale research batches up to large-scale clinical production, with proven scalability from 1L to 1,000L.
Insights for Developers
-
As gene therapy programs advance toward commercialization, the discipline required starts to look less like a sprint and more like…
-
Dr. Brianna Barrett, Ph.D., answers real developer questions about program manufacturing strategy with practical guidance shaped by supporting over 60…
-
This episode of 23 Questions highlights Lisa Genco Fisher and Quality team, one that plays a role in every stage…
-
An integrated strategy grounded in early planning across vector design, scalable production approaches, and analytical strategies enables developers to engage…